RE: The Waiting Game.10 Jul 2020 18:25
RNS Number : 3008Q
Synairgen plc
18 June 2020
Richard Marsden, CEO of Synairgen, commented: "The reduced incidence of COVID-19 demonstrates good progress in the battle to bring this disease under control, but a second wave of infection still presents a significant risk to public health. Synairgen's trial design, and its expansion nationally, lends itself to recruit additional patients more easily, particularly in the event of a second wave of this disease. In the meantime, we are on track to report the results of the 100 patients who have been successfully treated in the hospital setting in July."
Expecting news anytime now.